Dendreon cancer vaccine technology yields positive results

Seattle-based Dendreon Corp. said animal testing of an experimental cancer vaccine technology showed "promising" results, providing 100 percent protection against the development of cancer in laboratory mice.

The company said the alternative reading frame technology could allow it to design vaccines targeting several types of cancer, including those it already has in late-stage clinical trials, such as Provenge, which is in phase 3 trials for treating prostate cancer patients.

Dendreon said its researchers designed non-protein-derived immunogens and used them to immunize 10 lab mice, then introduced the well-known, tumor-associated antigen Her-2 as a target. All 10 immunized mice survived tumor free indefinitely, while 10 out of 10 control mice died within 35 days, the company said.

Dendreon said it has applied for a patent covering the compositions and methods that relate to alternative reading frame technology.

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.